权益分类	功能权益	普通用户	{{item.name}}会员
{{category.name}}	{{benefitItem.name}}

A Novel IL-35 Expressing Probiotic Platform for Inducing Allergen Specific Tolerance

用于诱导过敏原特异性耐受的新型 IL-35 表达益生菌平台

基本信息

批准号：
10450744
负责人：
Neil A Fanger
金额：
$ 97.95万
依托单位：
VIRTICI, LLC
依托单位国家：
美国
项目类别：
财政年份：
2020
资助国家：
美国
起止时间：
2020-05-01 至 2024-06-30
项目状态：
已结题

来源：
https://reporter.nih.gov/project-details/10450744
关键词：
Acute Allergens Allergic Americas Antigens Asthma Autoimmune Diseases Autoimmunity Automobile Driving Bacteria Benchmarking Blood Chemical Analysis CCR6 gene CD4 Positive T Lymphocytes Cells Centers for Disease Control and Prevention (U.S.)Cessation of life Chromosomes Clinic Clinical Collagen Arthritis Colony-forming units Country Data Set Dermatophagoides Antigens Development Disease Dose Event Extrinsic asthma FOXP3 gene Freeze Drying Genome Genomics Goals Growth Health Hematology Histopathology House mice Human Hypersensitivity Immune Immune System Diseases Immune Tolerance Immunologics Immunosuppressive Agents Incidence Individual Inflammation Interleukin-10 Intestines Lactococcus lactis Measures Mediating Modeling Monitor Mus Operon Oral Oral Administration Patients Persons Pharmacology and Toxicology Phase Physiological Probiotics Prophylactic treatment Protocols documentation Pyroglyphidae Reaction Regulatory T-Lymphocyte Research Respiratory Signs and Symptoms Severity of illness Small Business Innovation Research Grant Source Steroids Stimulus Symptoms T memory cell Therapeutic Toxic effect Toxicology Treatment Protocols airborne allergen asthma exacerbation asthmatic base cell bank clinical candidate desensitization dust mite allergy environmental allergen genome sequencing irritation mouse model novel novel therapeutics pharmacokinetics and pharmacodynamics pre-clinical prevent pyroglyphid side effect symptom treatment therapeutic target trafficking whole genome

项目摘要

Project Summary Our goal is to develop VTC-L35 as a novel tolerance-inducing probiotic platform for the treatment of asthma. According to the CDC, more than 25 million people in America suffer from asthma. Globally, nearly 350 million people suffer from asthma, with more than 300,000 annual deaths attributed to the disease (CDC). Because asthma is fundamentally a disease of immune dysregulation, many current asthma treatments are immunosuppressive agents, including steroids. While these are effective at managing asthma symptoms for many patients, the effects are temporary, have considerable side-effects, and require constant administration. Asthma “attacks” are triggered by a variety of environmental stimuli, the most common of which are aeroallergens. Desensitization protocols exist but are intensive and impractical given the fact that most asthmatics have multiple, often unidentified, allergens. As a result, new therapies are desperately needed to tolerize asthmatics against their own “personalized” allergens. Recently, our project team developed a novel Lactococcus lactis (L. lactis) research strain expressing IL-35 (VTC-L35)26. Oral administration of VTC-L35 effectively reduced the incidence and disease severity of inflammation in both prophylactic and treatment protocols in the mouse model of collagen-induced arthritis model (CIA). VTC-L35 induced CCR6+ and CCR6− CD39+ CD4+ Treg cells in CIA mice. Inquiry into their induction revealed that both CCR6+ and CCR6− Foxp3+/or− CD39+ CD4+ T cells act as the source of the IL-10 induced by VTC-L35. We believe that oral administration of VTC-L35 in the presence of an individual’s environmental allergens will induce antigen-specific regulatory cells and restore tolerance to an individual’s allergens, reversing asthma symptoms. To validate our approach, we plan to demonstrate that oral administration of VTC-L35 in the presence of low amounts of house dust mite (HDM) antigens prevents allergic and airway symptoms in a mouse model. Subsequently, we will develop and validate a genome-integrated clinical strain. The high-level aims of this Fast-track SBIR application are to 1) demonstrate that our VTC-L35 research strain induces tolerance in a mouse HDM allergy model with no detectable short-term toxicity; 2) develop and characterize a VTC-L35 clinical candidate expressing human IL-35 from a genome-integrated operon; and 3) develop non- GLP and GLP preclinical datasets to support VTC-L35 IND approval. Completion of this proposal will establish a novel IL-35-expressing probiotic platform that can be applied to treat asthma, allergies broadly and even an array of autoimmune diseases.

项目总结